Login:
 
Savill P. Newer drug therapies lower morbidity and mortality in acute coronary syndrome. Practitioner 2014; 258 (1772): 10

Newer drug therapies lower morbidity and mortality in acute coronary syndrome

23 Jun 2014Pais-up subscribers

The new ADP receptor antagonists significantly reduce deaths and cardiovascular morbidity compared with clopidogrel in patients with stable angina or acute coronary syndrome managed invasively, a meta-analysis has shown. These benefits were achieved without a significant increase in bleeding complications. The researchers identified eight randomised clinical trials comparing the new ADP receptor antagonists (prasugrel, ticagrelor and cangrelor) with clopidogrel in a total of 67,851 patients with stable angina or acute coronary syndrome.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article